NIH Funds Research to Explore a Cell Communication Process
News Aug 14, 2013
The National Institutes of Health announced today it will award $17 million this year for 24 research projects designed to improve scientists’ understanding of a newly discovered type of cell-to-cell communication based on extracellular (outside the cell) RNA, also called exRNA. Through these awards, scientists will explore basic exRNA biology and develop tools and technologies that apply new knowledge about exRNA to the research, diagnosis and treatment of diseases. To unlock the potential of this new scientific field, the awarded research projects will address conditions in which exRNA could play a role, including many types of cancer, bone marrow disorders, heart disease, Alzheimer’s disease and multiple sclerosis.
The collaborative, cross-cutting Extracellular RNA Communication program is supported by the NIH Common Fund and led by a trans-NIH team that includes the National Center for Advancing Translational Sciences (NCATS); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute on Drug Abuse (NIDA); and National Institute of Neurological Disorders and Stroke (NINDS).
“We have a tremendous opportunity to explore a recently discovered novel way that cells communicate,” said NIH Director Francis S. Collins, M.D., Ph.D. “Expanding our understanding of this emerging scientific field could help us determine the role extracellular RNA plays in health and disease, and unlocking its mysteries may provide our nation’s scientists with new tools to better diagnose and treat a wide range of diseases.”
Scientists think exRNA can regulate many functions in the body and may have an important role in a variety of diseases, but they still know very little about basic exRNA biology. Most RNA works inside cells to translate genes into proteins that are necessary for organisms to function. Other types of RNA control which proteins and the amount of those proteins the cells make. Until recently, scientists believed RNA worked mostly inside the cell that produced it. Now, recent findings show cells can release RNA in the form of exRNA to travel through body fluids and affect other cells. ExRNA can act as a signaling molecule, communicating with other cells and carrying information from cell to cell throughout the body.
Researchers hope to use some kinds of exRNA as biomarkers, or indicators of the presence, absence or stage of a disease. These biomarkers may enable scientists to understand and diagnose diseases earlier and more effectively. Scientists also will use exRNA to develop molecular treatments for diseases.
“To harness exRNA’s enormous potential for diagnostics and therapeutics in a broad range of diseases, we first need to understand more about different types of exRNA, how cells make and release it, how it travels through the body, how it targets and affects specific cells, and how the amount and type of exRNA can change in disease,” said James Anderson, M.D., Ph.D., director of the Division of Program Coordination, Planning, and Strategic Initiatives, which oversees the NIH Common Fund. “Awards in this exciting new field will help advance our collective understanding of exRNA communication and will enable research in many biomedical research fields.”
Multidisciplinary teams of investigators will carry out research projects in a number of critical scientific areas. NCATS will administer 18 awards through which researchers will develop biomarkers from exRNA and design new ways to use exRNA in treatments. NCI will oversee five projects that address how cells make and release exRNA (biogenesis), how and where exRNA travels through body fluids to other cells (biodistribution), how cells take in exRNA that is traveling through body fluids (uptake), and how exRNA changes the function of cells (effector functions). NIDA will support a project to develop a Data Management and Resource Repository that will house all of the data generated by these projects, including a public ExRNA Atlas website to serve as a community-wide resource for exRNA research standards, protocols, data, tools and technology. Scientists working on these projects will form an ExRNA Consortium to collaborate, share information, and spread knowledge to the larger scientific community and public.
“NCATS develops, demonstrates and disseminates new technologies that catalyze improvements in human health” said NCATS Director Christopher P. Austin, M.D. “These awards epitomize that mission, delving into a brand new area of science to discover new targets for interventions, diagnostics, biomarkers and therapeutics — all of which will speed the path from discovery to improved health.”
The 24 awards are milestone-driven cooperative agreements. Individual projects will be supported for up to five years, except for the Data Management and Resource Repository, which could be supported longer. To learn more about the research projects, visit http://commonfund.nih.gov/exrna/fundedresearch.
Later this year, NIH plans to issue a request for applications to develop an exRNA reference profile, which is a catalog of the types of exRNA found in various body fluids from healthy humans. NHLBI will lead this effort to enable studies on how exRNA profiles of people with diseases differ from those of healthy people.
New Automated Screening Method for Identifying Drug CandidatesNews
Scientists at DESY have developed a new method that enables automated and fast screening of promising drug candidates.READ MORE
Progressive Kidney Disease: New Compound Restores Kidney FunctionNews
A team led by researchers describe a new approach to prevent death in these essential kidney cells. Studying multiple animal models of kidney disease, the team discovered a compound that can impede loss of the filtration cells and restore kidney function.READ MORE
3D Mini Brains Accelerate Drug Screening and Brain Function ResearchNews
Houston Methodist neuroscientist Robert Krencik, Ph.D., and his team have developed a new system to reduce the time it takes to grow these brain models, which will give them the ability to screen drugs and study what’s behind disease-causing mutations more quickly.READ MORE